WuXi STA Opens Nucleic Acid Drug Manufacturing Facility

Nucleic acid drugs have the potential to treat neuromuscular and metabolic diseases where small molecule drugs have failed.

AsianScientist (Feb. 5, 2020) – STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of China-headquartered biotechnology company WuXi AppTec, has opened its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China.

As of 2019, eight nucleic acid drugs have been approved by the US Food and Drug Administration for the treatment of diseases, including nervous muscular diseases and familial metabolic diseases. With the growing interest in nucleic acid drugs, WuXi STA’s new facility aims to help customers accelerate such drugs to market with its oligonucleotide platform.

The platform covers the development and manufacturing of various types of oligonucleotide modalities including DNA, RNA, morpholino oligonucleotide and peptide conjugates.

“By leveraging our small-molecule chemical, manufacturing and control technology and capability platform, as well as [our] global-standard quality system, WuXi STA provides a robust one-stop shop for oligonucleotide innovators,” said Dr. Chen Minzhang, CEO of WuXi STA.


Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist